Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Melissa Jöe

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Neural Regeneration Research|January 17, 2025
Targeting Wallerian degeneration in glaucomaMelissa Jöe, Pete A Williams
Cells|February 4, 2021
Targeting Diet and Exercise for Neuroprotection and Neurorecovery in GlaucomaJames R Tribble, Flora Hui, Melissa Jöe, et al.
Acta Neuropathologica Communications|September 8, 2023
Pyrroloquinoline quinone drives ATP synthesis in vitro and in vivo and provides retinal ganglion cell neuroprotectionAlessio Canovai, James R Tribble, Melissa Jöe, et al.
ACS Medicinal Chemistry Letters|April 15, 2026
Potent Neuronal Nicotinamide Adenine Dinucleotide-Boosting Tetrahydroquinoxalines: Structure-Activity Relationships and Early Drug Metabolism and Pharmacokinetics EvaluationPetra Cuřínová, Melissa Jöe, Filip Cesar, et al.
Nature Communications|September 17, 2024
Author Correction: NMNAT2 is a druggable target to drive neuronal NAD productionJames R Tribble, Melissa Jöe, Carmine Varricchio, et al.
Nature Communications|July 24, 2024
NMNAT2 is a druggable target to drive neuronal NAD productionJames R Tribble, Melissa Jöe, Carmine Varricchio, et al.
Redox Biology|May 1, 2021
Nicotinamide provides neuroprotection in glaucoma by protecting against mitochondrial and metabolic dysfunctionJames R Tribble, Amin Otmani, Shanshan Sun, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Neural Regeneration Research|January 17, 2025
Targeting Wallerian degeneration in glaucomaMelissa Jöe, Pete A Williams
Cells|February 4, 2021
Targeting Diet and Exercise for Neuroprotection and Neurorecovery in GlaucomaJames R Tribble, Flora Hui, Melissa Jöe, et al.
Acta Neuropathologica Communications|September 8, 2023
Pyrroloquinoline quinone drives ATP synthesis in vitro and in vivo and provides retinal ganglion cell neuroprotectionAlessio Canovai, James R Tribble, Melissa Jöe, et al.
ACS Medicinal Chemistry Letters|April 15, 2026
Potent Neuronal Nicotinamide Adenine Dinucleotide-Boosting Tetrahydroquinoxalines: Structure-Activity Relationships and Early Drug Metabolism and Pharmacokinetics EvaluationPetra Cuřínová, Melissa Jöe, Filip Cesar, et al.
Nature Communications|September 17, 2024
Author Correction: NMNAT2 is a druggable target to drive neuronal NAD productionJames R Tribble, Melissa Jöe, Carmine Varricchio, et al.
Nature Communications|July 24, 2024
NMNAT2 is a druggable target to drive neuronal NAD productionJames R Tribble, Melissa Jöe, Carmine Varricchio, et al.
Redox Biology|May 1, 2021
Nicotinamide provides neuroprotection in glaucoma by protecting against mitochondrial and metabolic dysfunctionJames R Tribble, Amin Otmani, Shanshan Sun, et al.
Pageof 1